Scheithauer Bernd W, Erdogan Sibel, Rodriguez Fausto J, Burger Peter C, Woodruff James M, Kros Johan M, Gokden Murat, Spinner Robert J
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Am J Surg Pathol. 2009 Mar;33(3):325-38. doi: 10.1097/PAS.0b013e31818d6470.
Malignant peripheral nerve sheath tumors (MPNSTs) arising from cranial nerves or their branches are very uncommon. The literature consists mainly of isolated case reports and small series. We identified 17 such cases in 14 males and 3 females. With one exception, the tumors affected adults (age range 5 to 69 y, mean 39, median 32). Sites of involvement included vestibular nerves (n=6), vagal nerves (n=4), facial nerves (n=3) (1 centered in the geniculate ganglion), and 2 unspecified cranial nerves in the posterior fossa. In addition, 1 tumor involved the optic chiasm (n=1). Only 1 tumor arose in brain parenchyma of (frontal lobe). All but 3 lesions were intracranial. Five tumors arose in patients who satisfied clinical criteria for neurofibromatosis type 1 (NF1). One patient with a vestibular tumor and presumed NF2 had previously undergone resection of a contralateral vestibular cellular schwannoma. One posterior fossa tumor was a malignant melanotic schwannoma. Four patients had postirradiation malignant peripheral nerve sheath tumors, 2 having been treated for optic chiasm glioma, both being NF1 affected. One patient was irradiated for hypothalamic pilocytic astrocytoma and another for cervical Hodgkin disease. Identifiable precursor lesions included schwannoma (n=4), plexiform neurofibroma (n=2), and solitary intraneural neurofibroma (n=2). All tumors were histologically high grade (6 grade III and 10 grade IV). Three tumors showed heterologous elements, 2 osseous, and 1 rhabdomyoblastic. More often scattered than diffuse, S-100 protein staining was noted in 11 of 16 tumors and variable collagen IV staining in 10 of the 16. Immunoreactivity for p53 protein was diffuse and strong in 7 of 11 tumors. Twelve patients died within 17 months to 3 years of diagnosis, 1 was lost to follow-up, 2 are very recent cases, and 2 patients are currently alive, 1 after 2 recurrences, and another with spinal leptomeningeal metastases. Malignant cranial nerve sheath tumors are rare and are associated with the same poor prognosis as those of spinal nerves at other sites.
起源于颅神经或其分支的恶性外周神经鞘瘤(MPNST)非常罕见。文献主要由孤立的病例报告和小系列病例组成。我们确定了17例此类病例,其中男性14例,女性3例。除1例例外,肿瘤均累及成年人(年龄范围5至69岁,平均39岁,中位数32岁)。受累部位包括前庭神经(n = 6)、迷走神经(n = 4)、面神经(n = 3)(1例位于膝状神经节)以及后颅窝2条未明确的颅神经。此外,1例肿瘤累及视交叉(n = 1)。仅1例肿瘤起源于脑实质(额叶)。除3例病变外,其余均位于颅内。5例肿瘤发生于符合1型神经纤维瘤病(NF1)临床标准的患者。1例患有前庭肿瘤且推测为NF2的患者此前已接受对侧前庭细胞性神经鞘瘤切除术。1例后颅窝肿瘤为恶性黑色素性神经鞘瘤。4例患者患有放疗后恶性外周神经鞘瘤,其中2例曾接受视交叉胶质瘤治疗,均为NF1患者。1例患者因下丘脑毛细胞型星形细胞瘤接受放疗,另1例因颈部霍奇金病接受放疗。可识别的前驱病变包括神经鞘瘤(n = 4)、丛状神经纤维瘤(n = 2)和孤立性神经内神经纤维瘤(n = 2)。所有肿瘤组织学分级均为高级别(6例为III级,10例为IV级)。3例肿瘤显示异源性成分,2例为骨成分,1例为横纹肌母细胞成分。S - 100蛋白染色多为散在而非弥漫性,16例肿瘤中有11例可见,16例中有10例胶原IV染色各异。11例肿瘤中有7例p53蛋白免疫反应呈弥漫性且强阳性。12例患者在诊断后17个月至3年内死亡,1例失访,2例为近期病例,2例患者目前存活,1例经历2次复发,另1例有脊髓软脑膜转移。恶性颅神经鞘瘤罕见,且与其他部位脊神经的恶性颅神经鞘瘤预后同样不良。